Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Spotlight on CCK-B antagonists for anxiety

Jan. 27, 1997

Medeva begins full development of ADHD Rx

Jan. 27, 1997

NK1 antagonists from Takeda

Jan. 27, 1997

Excitatory amino acid receptor ligands from Schering AG

Jan. 27, 1997

FDA approves Royce's generic narcotic pain reliever

Jan. 24, 1997

Royce Laboratories receives FDA approval for alprazolam

Jan. 24, 1997

SIBIA receives patent coverage for antiparkinson compounds

Jan. 24, 1997

Glaxo Wellcome selects anticonvulsant compound for further study

Jan. 24, 1997

New AMPA receptor modulator described by Servier

Jan. 23, 1997

BMS cognition enhancer not superior to placebo in clinical study

Jan. 23, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 29, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...